Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., . . . Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol.
Citação norma ChicagoSchmid, Peter, et al. "Fulvestrant Plus Vistusertib Vs Fulvestrant Plus Everolimus Vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial." JAMA Oncol 2019.
Citação norma MLASchmid, Peter, et al. "Fulvestrant Plus Vistusertib Vs Fulvestrant Plus Everolimus Vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial." JAMA Oncol 2019.